Home | GSK
IDRx was a clinical-stage biopharmaceutical company developing precision oncology therapies for gastrointestinal stromal tumors (GIST). Its lead asset IDRX-42, a highly selective KIT inhibitor licensed from Merck KGaA, demonstrated activity against all clinically relevant primary and secondary KIT mutations. IDRx was founded in 2021 by Alexis Borisy, George Demetri, and Nicholas Lydon, and was acquired by GSK in February 2025 for approximately $1 billion upfront.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountAug 2022
Create a free account to see which investors have funded this company.
Create Free Account
OneOncology empowers oncology practices with advanced tools and capabilities to help physicians d...
Healthcare company in Europe
Mehiläinen is a leading Finnish private healthcare company providing medical, health, and special...
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
Klick Health is a healthcare marketing and commercialization agency serving life sciences and pha...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
